• Corpus ID: 40902735

Drug selection in a regulated society: the Norwegian experience.

@article{Bakke1984DrugSI,
  title={Drug selection in a regulated society: the Norwegian experience.},
  author={Olav M. Bakke},
  journal={Hospital formulary},
  year={1984},
  volume={19 5},
  pages={
          411-2, 415, 418 passim
        }
}
  • O. Bakke
  • Published 1984
  • Medicine
  • Hospital formulary
Norway has strictly regulated the introduction and marketing of drugs for more than 50 years. The system is a state owned whole-sale monopoly with nationwide distribution. Marketing approvals must satisfy a medical "need" clause and are granted and reviewed every 5 years by the " Specialties ' Committee." Although clinical trials are not mandatory for drug approval, relative efficacy and benefit/risk considerations make them desirable. Assessment of clinical data is based on reviews by outside… 
Whatever happened to the Norwegian Medical Need Clause? Lessons for current debates in EU pharmaceutical regulation.
TLDR
Norway's experience with its MNC in light of contemporary debates in European health policy is reviewed to discuss the potential contribution of an MNC-style regulation to improving health, reducing illness, ensuring sustainable health systems and fostering pharmaceutical innovation.
Less Is More: Norwegian Drug Regulation, Antibiotic Policy, and the “Need Clause”
TLDR
The Norwegian drug regulatory system, and particularly its “need clause,” has been invoked in international debates but not previously studied in detail and demonstrates how regulatory procedures can be used to limit market entrance and promote appropriate use simultaneously.
Seventeen years' experience of a voluntarily based drug rationalisation programme in hospital.
TLDR
It is concluded that the second drug rationalisation programme model substantially improves the cost effective use of drugs in hospital and furthermore has the potential of being extended to general practice, especially in types of prescribing that are common to both forms of patient care.
Pharmacoeconomics of antimicrobial usage in the secondary care sector
TLDR
The two studies undertalcen for this thesis have attempted to demonstrate how the combination of the costs of treatment with clinical and process measures of outcome could be used to avoid resource wastage.